These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

73 related articles for article (PubMed ID: 11026031)

  • 21. Tamoxifen for early breast cancer.
    Nurs Times; 2001 Jun 21-27; 97(25):41. PubMed ID: 11957988
    [No Abstract]   [Full Text] [Related]  

  • 22. [Occult multicentric breast cancer].
    Vtorushin SV; Zab'ialova MV; Glushchenko SA; Perel'muter VM; Slonimskaia EM
    Vopr Onkol; 2009; 55(1):38-41. PubMed ID: 19435197
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical significance of basal-like subtype in triple-negative breast cancer.
    Yamamoto Y; Ibusuki M; Nakano M; Kawasoe T; Hiki R; Iwase H
    Breast Cancer; 2009; 16(4):260-7. PubMed ID: 19701681
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Comparison of radiometric, immunometric, and immunohistochemical methods for the determination of hormonal receptors and quality control of other prognostic parameters in the characterization of carcinoma of the breast].
    Piffanelli A; Pelizzola D; Giovannini G; Catozzi L; Uccelli L; Barozzi R; Giganti M
    Pathologica; 1992; 84(1094):61-4. PubMed ID: 1363758
    [No Abstract]   [Full Text] [Related]  

  • 25. Clinical, histopathologic, and immunohistochemical features of microglandular adenosis and transition into in situ and invasive carcinoma.
    Khalifeh IM; Albarracin C; Diaz LK; Symmans FW; Edgerton ME; Hwang RF; Sneige N
    Am J Surg Pathol; 2008 Apr; 32(4):544-52. PubMed ID: 18300793
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Tumor-specific expression of vascular endothelial growth factor receptor 2 but not vascular endothelial growth factor or human epidermal growth factor receptor 2 is associated with impaired response to adjuvant tamoxifen in premenopausal breast cancer.
    Rydén L; Jirström K; Bendahl PO; Fernö M; Nordenskjöld B; Stål O; Thorstenson S; Jönsson PE; Landberg G
    J Clin Oncol; 2005 Jul; 23(21):4695-704. PubMed ID: 16034044
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Role of prognostic factors in evaluation of survival in breast cancer].
    Popârlan T; Muscă S
    Rev Med Chir Soc Med Nat Iasi; 2010; 114(1):147-51. PubMed ID: 20509292
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Clinical-biological meaning of progesterone receptor status in 118 estrogen receptor positive infiltrating ductal carcinomas of the breast in post-menopausal women].
    Ruibal A; Schneider J; Arias J; del Río MC; Núnez MJ; Tejerina A
    Rev Esp Med Nucl; 2000 Jun; 19(3):244-6. PubMed ID: 11062090
    [No Abstract]   [Full Text] [Related]  

  • 29. Comparison of EGFR, c-erbB-2 product and ras p21 immunohistochemistry as prognostic markers in primary breast cancer.
    Hainsworth PJ; Henderson MA; Stillwell RG; Bennett RC
    Eur J Surg Oncol; 1991 Feb; 17(1):9-15. PubMed ID: 1671658
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [erbB2 as a prognostic factor of breast cancers].
    Nishimura R; Nagao K; Miyayama H
    Nihon Rinsho; 2000 Apr; 58 Suppl():407-12. PubMed ID: 11026025
    [No Abstract]   [Full Text] [Related]  

  • 31. Estrogen receptor-negative and human epidermal growth factor receptor 2-negative breast cancer tissue have the highest Ki-67 labeling index and EGFR expression: gene amplification does not contribute to EGFR expression.
    Umemura S; Takekoshi S; Suzuki Y; Saitoh Y; Tokuda Y; Osamura RY
    Oncol Rep; 2005 Aug; 14(2):337-43. PubMed ID: 16012712
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [The receptor status between in primary tumor and in its involved regional node referring to estrogen receptor and epidermal growth factor receptor in human breast cancer: preliminary report].
    Mori T; Morimoto T; Komaki K; Monden Y
    Nihon Geka Gakkai Zasshi; 1989 Oct; 90(10):1820. PubMed ID: 2594014
    [No Abstract]   [Full Text] [Related]  

  • 33. Prostate-specific antigen value as a marker in breast cancer.
    Narita D; Cimpean AM; Anghel A; Raica M
    Neoplasma; 2006; 53(2):161-7. PubMed ID: 16575473
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Bel-2 as a prognostic factor of breast cancers].
    Watanabe K; Kawabata K; Ozaki S; Fujita H; Kojima Y; Tsuda H
    Nihon Rinsho; 2000 Apr; 58 Suppl():423-8. PubMed ID: 11026028
    [No Abstract]   [Full Text] [Related]  

  • 35. [CD44 as a prognostic factor of breast cancers].
    Fujimori M
    Nihon Rinsho; 2000 Apr; 58 Suppl():418-22. PubMed ID: 11026027
    [No Abstract]   [Full Text] [Related]  

  • 36. Variable performance of commercial epidermal growth factor receptor antibodies in detection of basal-like breast cancer.
    Won JR; Gao D; Grant D; Cupples J; Rahemtulla A; Wolber R; Nielsen TO; Gilks CB
    Histopathology; 2012 Sep; 61(3):518-9. PubMed ID: 22642766
    [No Abstract]   [Full Text] [Related]  

  • 37. [Recent prognostic factors of breast cancers].
    Sato F; Umemura S; Osamura Y
    Nihon Rinsho; 2000 Apr; 58 Suppl():478-80. PubMed ID: 11026037
    [No Abstract]   [Full Text] [Related]  

  • 38. Expression of epidermal growth-factor receptor in lymphangiomatosis: a new therapeutic target?
    Mertsching H; Walles T; Bakker G; Wildfang I; Macchiarini P
    Lancet Oncol; 2004 Jun; 5(6):353. PubMed ID: 15172355
    [No Abstract]   [Full Text] [Related]  

  • 39. The Nottingham Research Programme in breast cancer.
    Blamey RW
    Aust N Z J Surg; 1984 Jun; 54(3):191-9. PubMed ID: 6590014
    [No Abstract]   [Full Text] [Related]  

  • 40. [Pathological (classical) prognostic factors of breast cancers].
    Umekita Y; Yoshida H
    Nihon Rinsho; 2000 Apr; 58 Suppl():395-400. PubMed ID: 11026023
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.